^(131)I在PN+期甲状腺乳头状癌治疗中的临床应用  

Clinical application of ^(131)I in the treatment of PN+stage papillary thyroid carcinoma

作　　者：施伟军[1] 李林法[1] 龙斌[1] 易贺庆[1] 王文栋[1] 

机构地区：[1]浙江省肿瘤医院核医学科,浙江杭州310000

出　　处：《中国现代医生》2017年第11期19-21,25,共4页China Modern Doctor

基　　金：浙江省医药卫生科技计划项目(2017KY025)

摘　　要：目的研究^(131)I在PN+期甲状腺乳头状癌淋巴结清扫中的作用。方法选取符合入组标准的甲状腺乳头状癌患者72例,随机分为^(131)I组和对照组,每组36例,统计各组检获淋巴结数目,微小淋巴结数目和淋巴结转移率。结果 ^(131)I组检测出淋巴结(5.18±0.63)枚/例,微小淋巴结检出率为21.0%,对照组检测出淋巴结(3.77±0.51)枚/例,微小淋巴结检出率为11.8%,差异无统计学意义(P>0.05);^(131)I组淋巴结转移率、复发率、生存率分别为19.9%、5.6%、97.2%,明显优于对照组的25.7%、19.4%、86.1%(P<0.05)。结论采用^(131)I对PN+期甲状腺乳头状癌有助于减少甲状腺乳头状癌复发和转移的几率。Objective To study the role of ^131I in lymph node dissection of papillary thyroid carcinoma in PN＋stage. Methods A total of 72 patients with papillary thyroid carcinoma meeting the inclusion criteria were chosen and randomly divided into ^131I group and control group, with 36 cases in each group. The number of lymph nodes,the number of tiny lymph nodes and lymph node metastasis rate between the two groups were measured. Results There Were （5.18± 0.63） pieces/cases of lymph nodes detected in the ^131I group, and the detection rate of the small lymph nodes in the ^131I group was 21.0%（3.77±0.51） pieces/cases of the lymph nodes were detected in the control group, and the detection rate of the small lymph nodes was 11.8%. There was no significant difference between the two groups （P〉0.05）. The lymph node metastasis rate, recurrence rate and survival rate in the ^131I group were 19.9%, 5.6% and 97.2%, respectively, significantly higher than those in the control group （25.7%, 19.4%, 86.1%）（P〈0.05）. Conclusion The use of ^131I in PN＋ stage thyroid papillary carcinoma can help reduce the risk of recurrence and metastasis of papillary thyroid carcinoma.

关 键 词：^131I 甲状腺乳头状癌 淋巴结 淋巴转移 

分 类 号：R736.1[医药卫生—肿瘤]